中国临床药学杂志

目的 构建新型抗肿瘤药物适应证审核系统，探讨其在处方前置审核中的效果与作用。方法 基于医院信息管理系统（HIS）开发了新型抗肿瘤药物适应证审核系统，该系统依据7个审方维度对相关处方进行前置审核。收集2021年7月至12月（应用前）与2022年1月至2023年6月（应用后）所有新型抗肿瘤药物处方。对比分析审核系统应用前后门诊处方/住院医嘱的适应证合理率，并分析前置审核质控指标和拦截问题。结果 系统应用前，门诊处方和住院医嘱的适应证合理率分别为83.76%和95.70%；应用后，处方与医嘱适应证合理率较系统应用前有显著提升（P<0.001），分别为97.65%和99.62%。门诊处方和住院医嘱的前置干预成功率分别为71.21%和100%，假阳性率分别为17.23%和2.82%；假阴性率分别为0.92%和0.38%。结论 新型抗肿瘤药物适应证审核系统在处方前置审核中有助于提高新型抗肿瘤药物的适应证合理率，促进合理用药。

AIM To establish a drug indication review system for novel antineoplastic agents and investigate its effectiveness and role in pre-prescription review. METHODS A system for reviewing indications of novel antineoplastic agents had been developed based on the hospital information system(HIS). The system performed pre-dispensing reviews of relevant prescriptions according to seven prescription review dimensions. All prescriptions of novel antineoplastic agents were collected from July to December 2021(before application) and from January 2022 to June 2023(after application). A comparative analysis of the rationality rate of prescription indications was conducted before and after the application of the system. In addition, an analysis of the quality control indexes of front-end auditing was conducted, as well as a breakdown of interception problems. RESULTS Prior to the introduction of the system, the reasonable rate of indications of outpatient prescriptions and inpatient medical orders was 83.76% and 95.70%, respectively. Following the implementation of the system, a notable increase in the reasonable rates of prescriptions and medical orders was observed in comparison to the previous rates(P < 0.001), which were 97.65% and 99.62%, respectively. The success rate of the intervention prior to the prescription and medical orders taking effect was 71.21% and 100%, respectively. The falsepositive rates were 17.23% and 2.82%, and the false-negative rates were 0.92% and 0.38%. CONCLUSION The drug indication review system enhances the rationality rate of indications for novel antineoplastic agents during pre-prescription review and promotes rational drug use.